A 55-year-old postmenopausal woman on tamoxifen for breast cancer for 5 years presents with postmenopausal bleeding. Transvaginal ultrasound shows endometrial thickness of 9 mm (the endometrial echo is heterogeneous). What is the appropriate investigation?
- A Hysteroscopy with directed biopsy, as standard endometrial thickness thresholds do not apply to tamoxifen users with bleeding ✓
- B Repeat TVUS in 6 months as tamoxifen causes subepithelial stromal hypertrophy, not true endometrial thickening
- C Endometrial aspiration (Pipelle) biopsy in the outpatient setting is sufficient
- D MRI pelvis to differentiate tamoxifen effect from carcinoma
Explanation
Tamoxifen-associated endometrial thickening on TVUS is often artifactual (due to subepithelial stromal proliferation and cystic change mimicking thickening), making TVUS unreliable for ruling out endometrial cancer in tamoxifen users. However, postmenopausal bleeding in any tamoxifen user requires histological evaluation regardless of TVUS findings. The recommended approach is office hysteroscopy with directed biopsy, which allows direct visualisation of the endometrium and targeted sampling of suspicious areas. Pipelle alone may miss focal pathology. MRI is useful for staging but not for initial diagnosis.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.